Bioscience Across the North to Benefit from New United Life Sciences Collaboration
News Oct 15, 2014
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) have announced the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow’s members in the north of the UK and the wider UK sector.
Today the partnership also publishes the Life Sciences Manifesto 2015 - 2020 which is being launched at the BIA’s UK Bioscience Forum in London. Led by the BIA, the four organizations have worked closely together on the Manifesto to pinpoint the key issues for the sector and make policy recommendations to government. Its three core messages to policy makers are:
• retain focus on strategically important technologies such as regenerative medicine and synthetic biology, which hold great potential to benefit the UK economy;
• ensure a supportive tax and finance environment through continuing policies such as the Biomedical Catalyst, R&D Tax Credits and the Patent Box; and
• support new flexible routes to licensing, evaluation, uptake and reimbursement of cutting edge medicines and treatments to facilitate swift patient access. A centrally funded and reimbursed Early Access to Medicines Scheme and full utilization of the European Medicine Agency’s Adaptive Licensing pilot will be required to achieve this aim.
Going forward United Life Sciences will:
• Hold a series of UK road shows to enable early stage companies access capital, understand the evolving policy landscape and grow their businesses;
• Promote and provide discounts for members on each other’s events; and
• Work together to provide a combined approach at large international events.
The group has been working closely together informally for two years, and has already hosted several joint events both in the UK and overseas. The partnership will also be seeking new ways to collaborate with others in the sector.
Announcing the new partnership, Harriet Fear, Chief Executive Officer of One Nucleus, said: “Collaboration and partnership based on mutual respect and trust are the key hallmarks of successful organizations in bioscience and United Life Sciences works in this way too - it’s in my DNA to support the UK after 21 years of serving my country as a diplomat. Collaboration, as so many of our members are aware, is vitally important”.
Dr Geoff Davison, Chief Executive Officer of Bionow, said: “By working together we avoid duplication of effort, recognizing that all our members are stretched in terms of their time and resources, plus it recognizes the strengths and expertise of each of the four organizations. The partnership is totally focused upon and driven by the needs of the sector and representing over 1000 businesses means the group has international critical mass and clout.”
Steve Bates, Chief Executive Officer of the BIA, said: “Through this collaboration, all four organizations are fully committed to providing a united front and critically, one voice, to the government via the lobbying and advocacy work that the BIA undertakes for the sector.”
Lin Bateson, Executive Director of Biopartner UK, said: “Linking up to provide a combined approach will help to focus international attention on UK bioscience expertise to encourage growth, inward investment, and much-needed funding.”
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
3D Spheroids Help Scientists Discover Smarter Cancer DrugsNews
An innovative new method to screen for potential cancer drugs. The technique makes use of tiny, three-dimensional ball-like aggregates of cells called spheroids. These structures can be used to interrogate hundreds or even thousands of compounds rapidly using a technique called high throughput screening.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018